Global Multiple Sclerosis (MS) Drugs Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Multiple Sclerosis (MS) Drugs market size was valued at US$ million in 2023. With growing demand in downstream market, the Multiple Sclerosis (MS) Drugs is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Multiple Sclerosis (MS) Drugs market. Multiple Sclerosis (MS) Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Multiple Sclerosis (MS) Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Multiple Sclerosis (MS) Drugs market.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Multiple Sclerosis (MS) Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Multiple Sclerosis (MS) Drugs market. It may include historical data, market segmentation by Type (e.g., Copaxone (Glatiramer Acetate, Copolymer 1), Novantrone (Mitoxantrone)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Multiple Sclerosis (MS) Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Multiple Sclerosis (MS) Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Multiple Sclerosis (MS) Drugs industry. This include advancements in Multiple Sclerosis (MS) Drugs technology, Multiple Sclerosis (MS) Drugs new entrants, Multiple Sclerosis (MS) Drugs new investment, and other innovations that are shaping the future of Multiple Sclerosis (MS) Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Multiple Sclerosis (MS) Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Multiple Sclerosis (MS) Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Multiple Sclerosis (MS) Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Multiple Sclerosis (MS) Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Multiple Sclerosis (MS) Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Multiple Sclerosis (MS) Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Multiple Sclerosis (MS) Drugs market.
Market Segmentation:
Multiple Sclerosis (MS) Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Multiple Sclerosis (MS) Drugs market?
What factors are driving Multiple Sclerosis (MS) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Multiple Sclerosis (MS) Drugs market opportunities vary by end market size?
How does Multiple Sclerosis (MS) Drugs break out type, application?
According to our LPI (LP Information) latest study, the global Multiple Sclerosis (MS) Drugs market size was valued at US$ million in 2023. With growing demand in downstream market, the Multiple Sclerosis (MS) Drugs is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Multiple Sclerosis (MS) Drugs market. Multiple Sclerosis (MS) Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Multiple Sclerosis (MS) Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Multiple Sclerosis (MS) Drugs market.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Multiple Sclerosis (MS) Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Multiple Sclerosis (MS) Drugs market. It may include historical data, market segmentation by Type (e.g., Copaxone (Glatiramer Acetate, Copolymer 1), Novantrone (Mitoxantrone)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Multiple Sclerosis (MS) Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Multiple Sclerosis (MS) Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Multiple Sclerosis (MS) Drugs industry. This include advancements in Multiple Sclerosis (MS) Drugs technology, Multiple Sclerosis (MS) Drugs new entrants, Multiple Sclerosis (MS) Drugs new investment, and other innovations that are shaping the future of Multiple Sclerosis (MS) Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Multiple Sclerosis (MS) Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Multiple Sclerosis (MS) Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Multiple Sclerosis (MS) Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Multiple Sclerosis (MS) Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Multiple Sclerosis (MS) Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Multiple Sclerosis (MS) Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Multiple Sclerosis (MS) Drugs market.
Market Segmentation:
Multiple Sclerosis (MS) Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Copaxone (Glatiramer Acetate, Copolymer 1)
- Novantrone (Mitoxantrone)
- Gilenya (Fingolimod, Fty720)
- Aubagio (Teriflunomide)
- Tecfidera (Dimethyl Fumarate)
- Firategrast (Sb683699, T-0047)
- Siponimod (Baf312)
- Others
- RRMS
- SPMS
- PPMS
- PRMS
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bayer AG
- Bayhill Therapeutics
- Biogen Idec
- Cinnagen
- Daiichi Sankyo
- Eli Lilly
- Fast Forward Llc
- Antisense Therapeutics
- Apitope
- Five Prime Therapeutics
- Genmab
- Artielle Immunotherapeutics
- Genzyme
- Glaxosmithkline
- Gw Pharmaceuticals
- Innate Immunotherapeutics
What is the 10-year outlook for the global Multiple Sclerosis (MS) Drugs market?
What factors are driving Multiple Sclerosis (MS) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Multiple Sclerosis (MS) Drugs market opportunities vary by end market size?
How does Multiple Sclerosis (MS) Drugs break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Multiple Sclerosis (MS) Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Multiple Sclerosis (MS) Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Multiple Sclerosis (MS) Drugs by Country/Region, 2019, 2023 & 2030
2.2 Multiple Sclerosis (MS) Drugs Segment by Type
2.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
2.2.2 Novantrone (Mitoxantrone)
2.2.3 Gilenya (Fingolimod, Fty720)
2.2.4 Aubagio (Teriflunomide)
2.2.5 Tecfidera (Dimethyl Fumarate)
2.2.6 Firategrast (Sb683699, T-0047)
2.2.7 Siponimod (Baf312)
2.2.8 Others
2.3 Multiple Sclerosis (MS) Drugs Sales by Type
2.3.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Multiple Sclerosis (MS) Drugs Sale Price by Type (2019-2024)
2.4 Multiple Sclerosis (MS) Drugs Segment by Application
2.4.1 RRMS
2.4.2 SPMS
2.4.3 PPMS
2.4.4 PRMS
2.5 Multiple Sclerosis (MS) Drugs Sales by Application
2.5.1 Global Multiple Sclerosis (MS) Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Multiple Sclerosis (MS) Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Multiple Sclerosis (MS) Drugs Sale Price by Application (2019-2024)
3 GLOBAL MULTIPLE SCLEROSIS (MS) DRUGS BY COMPANY
3.1 Global Multiple Sclerosis (MS) Drugs Breakdown Data by Company
3.1.1 Global Multiple Sclerosis (MS) Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2019-2024)
3.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Company (2019-2024)
3.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Multiple Sclerosis (MS) Drugs Sale Price by Company
3.4 Key Manufacturers Multiple Sclerosis (MS) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Multiple Sclerosis (MS) Drugs Product Location Distribution
3.4.2 Players Multiple Sclerosis (MS) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR MULTIPLE SCLEROSIS (MS) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Multiple Sclerosis (MS) Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Multiple Sclerosis (MS) Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Multiple Sclerosis (MS) Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Multiple Sclerosis (MS) Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Multiple Sclerosis (MS) Drugs Sales Growth
4.4 APAC Multiple Sclerosis (MS) Drugs Sales Growth
4.5 Europe Multiple Sclerosis (MS) Drugs Sales Growth
4.6 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Growth
5 AMERICAS
5.1 Americas Multiple Sclerosis (MS) Drugs Sales by Country
5.1.1 Americas Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024)
5.1.2 Americas Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024)
5.2 Americas Multiple Sclerosis (MS) Drugs Sales by Type
5.3 Americas Multiple Sclerosis (MS) Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Multiple Sclerosis (MS) Drugs Sales by Region
6.1.1 APAC Multiple Sclerosis (MS) Drugs Sales by Region (2019-2024)
6.1.2 APAC Multiple Sclerosis (MS) Drugs Revenue by Region (2019-2024)
6.2 APAC Multiple Sclerosis (MS) Drugs Sales by Type
6.3 APAC Multiple Sclerosis (MS) Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Multiple Sclerosis (MS) Drugs by Country
7.1.1 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024)
7.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024)
7.2 Europe Multiple Sclerosis (MS) Drugs Sales by Type
7.3 Europe Multiple Sclerosis (MS) Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Multiple Sclerosis (MS) Drugs by Country
8.1.1 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Type
8.3 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs
10.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
10.4 Industry Chain Structure of Multiple Sclerosis (MS) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Multiple Sclerosis (MS) Drugs Distributors
11.3 Multiple Sclerosis (MS) Drugs Customer
12 WORLD FORECAST REVIEW FOR MULTIPLE SCLEROSIS (MS) DRUGS BY GEOGRAPHIC REGION
12.1 Global Multiple Sclerosis (MS) Drugs Market Size Forecast by Region
12.1.1 Global Multiple Sclerosis (MS) Drugs Forecast by Region (2025-2030)
12.1.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Multiple Sclerosis (MS) Drugs Forecast by Type
12.7 Global Multiple Sclerosis (MS) Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Bayer AG
13.1.1 Bayer AG Company Information
13.1.2 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bayer AG Main Business Overview
13.1.5 Bayer AG Latest Developments
13.2 Bayhill Therapeutics
13.2.1 Bayhill Therapeutics Company Information
13.2.2 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bayhill Therapeutics Main Business Overview
13.2.5 Bayhill Therapeutics Latest Developments
13.3 Biogen Idec
13.3.1 Biogen Idec Company Information
13.3.2 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Biogen Idec Main Business Overview
13.3.5 Biogen Idec Latest Developments
13.4 Cinnagen
13.4.1 Cinnagen Company Information
13.4.2 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Cinnagen Main Business Overview
13.4.5 Cinnagen Latest Developments
13.5 Daiichi Sankyo
13.5.1 Daiichi Sankyo Company Information
13.5.2 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Daiichi Sankyo Main Business Overview
13.5.5 Daiichi Sankyo Latest Developments
13.6 Eli Lilly
13.6.1 Eli Lilly Company Information
13.6.2 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Eli Lilly Main Business Overview
13.6.5 Eli Lilly Latest Developments
13.7 Fast Forward Llc
13.7.1 Fast Forward Llc Company Information
13.7.2 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Fast Forward Llc Main Business Overview
13.7.5 Fast Forward Llc Latest Developments
13.8 Antisense Therapeutics
13.8.1 Antisense Therapeutics Company Information
13.8.2 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Antisense Therapeutics Main Business Overview
13.8.5 Antisense Therapeutics Latest Developments
13.9 Apitope
13.9.1 Apitope Company Information
13.9.2 Apitope Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Apitope Main Business Overview
13.9.5 Apitope Latest Developments
13.10 Five Prime Therapeutics
13.10.1 Five Prime Therapeutics Company Information
13.10.2 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Five Prime Therapeutics Main Business Overview
13.10.5 Five Prime Therapeutics Latest Developments
13.11 Genmab
13.11.1 Genmab Company Information
13.11.2 Genmab Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Genmab Main Business Overview
13.11.5 Genmab Latest Developments
13.12 Artielle Immunotherapeutics
13.12.1 Artielle Immunotherapeutics Company Information
13.12.2 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Artielle Immunotherapeutics Main Business Overview
13.12.5 Artielle Immunotherapeutics Latest Developments
13.13 Genzyme
13.13.1 Genzyme Company Information
13.13.2 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Genzyme Main Business Overview
13.13.5 Genzyme Latest Developments
13.14 Glaxosmithkline
13.14.1 Glaxosmithkline Company Information
13.14.2 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Glaxosmithkline Main Business Overview
13.14.5 Glaxosmithkline Latest Developments
13.15 Gw Pharmaceuticals
13.15.1 Gw Pharmaceuticals Company Information
13.15.2 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Gw Pharmaceuticals Main Business Overview
13.15.5 Gw Pharmaceuticals Latest Developments
13.16 Innate Immunotherapeutics
13.16.1 Innate Immunotherapeutics Company Information
13.16.2 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Innate Immunotherapeutics Main Business Overview
13.16.5 Innate Immunotherapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Multiple Sclerosis (MS) Drugs Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Multiple Sclerosis (MS) Drugs by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Multiple Sclerosis (MS) Drugs by Country/Region, 2019, 2023 & 2030
2.2 Multiple Sclerosis (MS) Drugs Segment by Type
2.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
2.2.2 Novantrone (Mitoxantrone)
2.2.3 Gilenya (Fingolimod, Fty720)
2.2.4 Aubagio (Teriflunomide)
2.2.5 Tecfidera (Dimethyl Fumarate)
2.2.6 Firategrast (Sb683699, T-0047)
2.2.7 Siponimod (Baf312)
2.2.8 Others
2.3 Multiple Sclerosis (MS) Drugs Sales by Type
2.3.1 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
2.3.2 Global Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type (2019-2024)
2.3.3 Global Multiple Sclerosis (MS) Drugs Sale Price by Type (2019-2024)
2.4 Multiple Sclerosis (MS) Drugs Segment by Application
2.4.1 RRMS
2.4.2 SPMS
2.4.3 PPMS
2.4.4 PRMS
2.5 Multiple Sclerosis (MS) Drugs Sales by Application
2.5.1 Global Multiple Sclerosis (MS) Drugs Sale Market Share by Application (2019-2024)
2.5.2 Global Multiple Sclerosis (MS) Drugs Revenue and Market Share by Application (2019-2024)
2.5.3 Global Multiple Sclerosis (MS) Drugs Sale Price by Application (2019-2024)
3 GLOBAL MULTIPLE SCLEROSIS (MS) DRUGS BY COMPANY
3.1 Global Multiple Sclerosis (MS) Drugs Breakdown Data by Company
3.1.1 Global Multiple Sclerosis (MS) Drugs Annual Sales by Company (2019-2024)
3.1.2 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2019-2024)
3.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue by Company (2019-2024)
3.2.1 Global Multiple Sclerosis (MS) Drugs Revenue by Company (2019-2024)
3.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company (2019-2024)
3.3 Global Multiple Sclerosis (MS) Drugs Sale Price by Company
3.4 Key Manufacturers Multiple Sclerosis (MS) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Multiple Sclerosis (MS) Drugs Product Location Distribution
3.4.2 Players Multiple Sclerosis (MS) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR MULTIPLE SCLEROSIS (MS) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Multiple Sclerosis (MS) Drugs Market Size by Geographic Region (2019-2024)
4.1.1 Global Multiple Sclerosis (MS) Drugs Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Multiple Sclerosis (MS) Drugs Market Size by Country/Region (2019-2024)
4.2.1 Global Multiple Sclerosis (MS) Drugs Annual Sales by Country/Region (2019-2024)
4.2.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue by Country/Region (2019-2024)
4.3 Americas Multiple Sclerosis (MS) Drugs Sales Growth
4.4 APAC Multiple Sclerosis (MS) Drugs Sales Growth
4.5 Europe Multiple Sclerosis (MS) Drugs Sales Growth
4.6 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Growth
5 AMERICAS
5.1 Americas Multiple Sclerosis (MS) Drugs Sales by Country
5.1.1 Americas Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024)
5.1.2 Americas Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024)
5.2 Americas Multiple Sclerosis (MS) Drugs Sales by Type
5.3 Americas Multiple Sclerosis (MS) Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Multiple Sclerosis (MS) Drugs Sales by Region
6.1.1 APAC Multiple Sclerosis (MS) Drugs Sales by Region (2019-2024)
6.1.2 APAC Multiple Sclerosis (MS) Drugs Revenue by Region (2019-2024)
6.2 APAC Multiple Sclerosis (MS) Drugs Sales by Type
6.3 APAC Multiple Sclerosis (MS) Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Multiple Sclerosis (MS) Drugs by Country
7.1.1 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024)
7.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024)
7.2 Europe Multiple Sclerosis (MS) Drugs Sales by Type
7.3 Europe Multiple Sclerosis (MS) Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Multiple Sclerosis (MS) Drugs by Country
8.1.1 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024)
8.1.2 Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024)
8.2 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Type
8.3 Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs
10.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
10.4 Industry Chain Structure of Multiple Sclerosis (MS) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Multiple Sclerosis (MS) Drugs Distributors
11.3 Multiple Sclerosis (MS) Drugs Customer
12 WORLD FORECAST REVIEW FOR MULTIPLE SCLEROSIS (MS) DRUGS BY GEOGRAPHIC REGION
12.1 Global Multiple Sclerosis (MS) Drugs Market Size Forecast by Region
12.1.1 Global Multiple Sclerosis (MS) Drugs Forecast by Region (2025-2030)
12.1.2 Global Multiple Sclerosis (MS) Drugs Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Multiple Sclerosis (MS) Drugs Forecast by Type
12.7 Global Multiple Sclerosis (MS) Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Bayer AG
13.1.1 Bayer AG Company Information
13.1.2 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bayer AG Main Business Overview
13.1.5 Bayer AG Latest Developments
13.2 Bayhill Therapeutics
13.2.1 Bayhill Therapeutics Company Information
13.2.2 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bayhill Therapeutics Main Business Overview
13.2.5 Bayhill Therapeutics Latest Developments
13.3 Biogen Idec
13.3.1 Biogen Idec Company Information
13.3.2 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Biogen Idec Main Business Overview
13.3.5 Biogen Idec Latest Developments
13.4 Cinnagen
13.4.1 Cinnagen Company Information
13.4.2 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Cinnagen Main Business Overview
13.4.5 Cinnagen Latest Developments
13.5 Daiichi Sankyo
13.5.1 Daiichi Sankyo Company Information
13.5.2 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Daiichi Sankyo Main Business Overview
13.5.5 Daiichi Sankyo Latest Developments
13.6 Eli Lilly
13.6.1 Eli Lilly Company Information
13.6.2 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Eli Lilly Main Business Overview
13.6.5 Eli Lilly Latest Developments
13.7 Fast Forward Llc
13.7.1 Fast Forward Llc Company Information
13.7.2 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Fast Forward Llc Main Business Overview
13.7.5 Fast Forward Llc Latest Developments
13.8 Antisense Therapeutics
13.8.1 Antisense Therapeutics Company Information
13.8.2 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Antisense Therapeutics Main Business Overview
13.8.5 Antisense Therapeutics Latest Developments
13.9 Apitope
13.9.1 Apitope Company Information
13.9.2 Apitope Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Apitope Main Business Overview
13.9.5 Apitope Latest Developments
13.10 Five Prime Therapeutics
13.10.1 Five Prime Therapeutics Company Information
13.10.2 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Five Prime Therapeutics Main Business Overview
13.10.5 Five Prime Therapeutics Latest Developments
13.11 Genmab
13.11.1 Genmab Company Information
13.11.2 Genmab Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.11.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Genmab Main Business Overview
13.11.5 Genmab Latest Developments
13.12 Artielle Immunotherapeutics
13.12.1 Artielle Immunotherapeutics Company Information
13.12.2 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Artielle Immunotherapeutics Main Business Overview
13.12.5 Artielle Immunotherapeutics Latest Developments
13.13 Genzyme
13.13.1 Genzyme Company Information
13.13.2 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.13.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Genzyme Main Business Overview
13.13.5 Genzyme Latest Developments
13.14 Glaxosmithkline
13.14.1 Glaxosmithkline Company Information
13.14.2 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 Glaxosmithkline Main Business Overview
13.14.5 Glaxosmithkline Latest Developments
13.15 Gw Pharmaceuticals
13.15.1 Gw Pharmaceuticals Company Information
13.15.2 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 Gw Pharmaceuticals Main Business Overview
13.15.5 Gw Pharmaceuticals Latest Developments
13.16 Innate Immunotherapeutics
13.16.1 Innate Immunotherapeutics Company Information
13.16.2 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
13.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Innate Immunotherapeutics Main Business Overview
13.16.5 Innate Immunotherapeutics Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Multiple Sclerosis (MS) Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Multiple Sclerosis (MS) Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Copaxone (Glatiramer Acetate, Copolymer 1)
Table 4. Major Players of Novantrone (Mitoxantrone)
Table 5. Major Players of Gilenya (Fingolimod, Fty720)
Table 6. Major Players of Aubagio (Teriflunomide)
Table 7. Major Players of Tecfidera (Dimethyl Fumarate)
Table 8. Major Players of Firategrast (Sb683699, T-0047)
Table 9. Major Players of Siponimod (Baf312)
Table 10. Major Players of Others
Table 11. Global Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 12. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Table 13. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2019-2024) & ($ million)
Table 14. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2019-2024)
Table 15. Global Multiple Sclerosis (MS) Drugs Sale Price by Type (2019-2024) & (USD/Pcs)
Table 16. Global Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 17. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Table 18. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2019-2024)
Table 19. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2019-2024)
Table 20. Global Multiple Sclerosis (MS) Drugs Sale Price by Application (2019-2024) & (USD/Pcs)
Table 21. Global Multiple Sclerosis (MS) Drugs Sales by Company (2019-2024) & (K Pcs)
Table 22. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2019-2024)
Table 23. Global Multiple Sclerosis (MS) Drugs Revenue by Company (2019-2024) ($ Millions)
Table 24. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company (2019-2024)
Table 25. Global Multiple Sclerosis (MS) Drugs Sale Price by Company (2019-2024) & (USD/Pcs)
Table 26. Key Manufacturers Multiple Sclerosis (MS) Drugs Producing Area Distribution and Sales Area
Table 27. Players Multiple Sclerosis (MS) Drugs Products Offered
Table 28. Multiple Sclerosis (MS) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 29. New Products and Potential Entrants
Table 30. Mergers & Acquisitions, Expansion
Table 31. Global Multiple Sclerosis (MS) Drugs Sales by Geographic Region (2019-2024) & (K Pcs)
Table 32. Global Multiple Sclerosis (MS) Drugs Sales Market Share Geographic Region (2019-2024)
Table 33. Global Multiple Sclerosis (MS) Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 34. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 35. Global Multiple Sclerosis (MS) Drugs Sales by Country/Region (2019-2024) & (K Pcs)
Table 36. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Country/Region (2019-2024)
Table 37. Global Multiple Sclerosis (MS) Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 38. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Country/Region (2019-2024)
Table 39. Americas Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024) & (K Pcs)
Table 40. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2019-2024)
Table 41. Americas Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 42. Americas Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2019-2024)
Table 43. Americas Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 44. Americas Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 45. APAC Multiple Sclerosis (MS) Drugs Sales by Region (2019-2024) & (K Pcs)
Table 46. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2019-2024)
Table 47. APAC Multiple Sclerosis (MS) Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 48. APAC Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2019-2024)
Table 49. APAC Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 50. APAC Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 51. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024) & (K Pcs)
Table 52. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2019-2024)
Table 53. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 54. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2019-2024)
Table 55. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 56. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 57. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024) & (K Pcs)
Table 58. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2019-2024)
Table 59. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 60. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2019-2024)
Table 61. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 62. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 63. Key Market Drivers & Growth Opportunities of Multiple Sclerosis (MS) Drugs
Table 64. Key Market Challenges & Risks of Multiple Sclerosis (MS) Drugs
Table 65. Key Industry Trends of Multiple Sclerosis (MS) Drugs
Table 66. Multiple Sclerosis (MS) Drugs Raw Material
Table 67. Key Suppliers of Raw Materials
Table 68. Multiple Sclerosis (MS) Drugs Distributors List
Table 69. Multiple Sclerosis (MS) Drugs Customer List
Table 70. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Region (2025-2030) & (K Pcs)
Table 71. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Americas Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2025-2030) & (K Pcs)
Table 73. Americas Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. APAC Multiple Sclerosis (MS) Drugs Sales Forecast by Region (2025-2030) & (K Pcs)
Table 75. APAC Multiple Sclerosis (MS) Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 76. Europe Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2025-2030) & (K Pcs)
Table 77. Europe Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 78. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2025-2030) & (K Pcs)
Table 79. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 80. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Type (2025-2030) & (K Pcs)
Table 81. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 82. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Application (2025-2030) & (K Pcs)
Table 83. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 84. Bayer AG Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 86. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 87. Bayer AG Main Business
Table 88. Bayer AG Latest Developments
Table 89. Bayhill Therapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 91. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 92. Bayhill Therapeutics Main Business
Table 93. Bayhill Therapeutics Latest Developments
Table 94. Biogen Idec Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 96. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 97. Biogen Idec Main Business
Table 98. Biogen Idec Latest Developments
Table 99. Cinnagen Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 101. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 102. Cinnagen Main Business
Table 103. Cinnagen Latest Developments
Table 104. Daiichi Sankyo Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 106. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 107. Daiichi Sankyo Main Business
Table 108. Daiichi Sankyo Latest Developments
Table 109. Eli Lilly Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 111. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 112. Eli Lilly Main Business
Table 113. Eli Lilly Latest Developments
Table 114. Fast Forward Llc Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 116. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 117. Fast Forward Llc Main Business
Table 118. Fast Forward Llc Latest Developments
Table 119. Antisense Therapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 121. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 122. Antisense Therapeutics Main Business
Table 123. Antisense Therapeutics Latest Developments
Table 124. Apitope Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. Apitope Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 126. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 127. Apitope Main Business
Table 128. Apitope Latest Developments
Table 129. Five Prime Therapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 130. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 131. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 132. Five Prime Therapeutics Main Business
Table 133. Five Prime Therapeutics Latest Developments
Table 134. Genmab Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 135. Genmab Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 136. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 137. Genmab Main Business
Table 138. Genmab Latest Developments
Table 139. Artielle Immunotherapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 140. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 141. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 142. Artielle Immunotherapeutics Main Business
Table 143. Artielle Immunotherapeutics Latest Developments
Table 144. Genzyme Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 145. Genzyme Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 146. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 147. Genzyme Main Business
Table 148. Genzyme Latest Developments
Table 149. Glaxosmithkline Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 150. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 151. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 152. Glaxosmithkline Main Business
Table 153. Glaxosmithkline Latest Developments
Table 154. Gw Pharmaceuticals Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 155. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 156. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 157. Gw Pharmaceuticals Main Business
Table 158. Gw Pharmaceuticals Latest Developments
Table 159. Innate Immunotherapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 160. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 161. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 162. Innate Immunotherapeutics Main Business
Table 163. Innate Immunotherapeutics Latest Developments
Table 1. Multiple Sclerosis (MS) Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Multiple Sclerosis (MS) Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Copaxone (Glatiramer Acetate, Copolymer 1)
Table 4. Major Players of Novantrone (Mitoxantrone)
Table 5. Major Players of Gilenya (Fingolimod, Fty720)
Table 6. Major Players of Aubagio (Teriflunomide)
Table 7. Major Players of Tecfidera (Dimethyl Fumarate)
Table 8. Major Players of Firategrast (Sb683699, T-0047)
Table 9. Major Players of Siponimod (Baf312)
Table 10. Major Players of Others
Table 11. Global Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 12. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Table 13. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2019-2024) & ($ million)
Table 14. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2019-2024)
Table 15. Global Multiple Sclerosis (MS) Drugs Sale Price by Type (2019-2024) & (USD/Pcs)
Table 16. Global Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 17. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Table 18. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2019-2024)
Table 19. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2019-2024)
Table 20. Global Multiple Sclerosis (MS) Drugs Sale Price by Application (2019-2024) & (USD/Pcs)
Table 21. Global Multiple Sclerosis (MS) Drugs Sales by Company (2019-2024) & (K Pcs)
Table 22. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Company (2019-2024)
Table 23. Global Multiple Sclerosis (MS) Drugs Revenue by Company (2019-2024) ($ Millions)
Table 24. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company (2019-2024)
Table 25. Global Multiple Sclerosis (MS) Drugs Sale Price by Company (2019-2024) & (USD/Pcs)
Table 26. Key Manufacturers Multiple Sclerosis (MS) Drugs Producing Area Distribution and Sales Area
Table 27. Players Multiple Sclerosis (MS) Drugs Products Offered
Table 28. Multiple Sclerosis (MS) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 29. New Products and Potential Entrants
Table 30. Mergers & Acquisitions, Expansion
Table 31. Global Multiple Sclerosis (MS) Drugs Sales by Geographic Region (2019-2024) & (K Pcs)
Table 32. Global Multiple Sclerosis (MS) Drugs Sales Market Share Geographic Region (2019-2024)
Table 33. Global Multiple Sclerosis (MS) Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 34. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 35. Global Multiple Sclerosis (MS) Drugs Sales by Country/Region (2019-2024) & (K Pcs)
Table 36. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Country/Region (2019-2024)
Table 37. Global Multiple Sclerosis (MS) Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 38. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Country/Region (2019-2024)
Table 39. Americas Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024) & (K Pcs)
Table 40. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2019-2024)
Table 41. Americas Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 42. Americas Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2019-2024)
Table 43. Americas Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 44. Americas Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 45. APAC Multiple Sclerosis (MS) Drugs Sales by Region (2019-2024) & (K Pcs)
Table 46. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2019-2024)
Table 47. APAC Multiple Sclerosis (MS) Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 48. APAC Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2019-2024)
Table 49. APAC Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 50. APAC Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 51. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024) & (K Pcs)
Table 52. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2019-2024)
Table 53. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 54. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2019-2024)
Table 55. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 56. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 57. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Country (2019-2024) & (K Pcs)
Table 58. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2019-2024)
Table 59. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 60. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2019-2024)
Table 61. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Type (2019-2024) & (K Pcs)
Table 62. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales by Application (2019-2024) & (K Pcs)
Table 63. Key Market Drivers & Growth Opportunities of Multiple Sclerosis (MS) Drugs
Table 64. Key Market Challenges & Risks of Multiple Sclerosis (MS) Drugs
Table 65. Key Industry Trends of Multiple Sclerosis (MS) Drugs
Table 66. Multiple Sclerosis (MS) Drugs Raw Material
Table 67. Key Suppliers of Raw Materials
Table 68. Multiple Sclerosis (MS) Drugs Distributors List
Table 69. Multiple Sclerosis (MS) Drugs Customer List
Table 70. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Region (2025-2030) & (K Pcs)
Table 71. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Americas Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2025-2030) & (K Pcs)
Table 73. Americas Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. APAC Multiple Sclerosis (MS) Drugs Sales Forecast by Region (2025-2030) & (K Pcs)
Table 75. APAC Multiple Sclerosis (MS) Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 76. Europe Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2025-2030) & (K Pcs)
Table 77. Europe Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 78. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2025-2030) & (K Pcs)
Table 79. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 80. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Type (2025-2030) & (K Pcs)
Table 81. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 82. Global Multiple Sclerosis (MS) Drugs Sales Forecast by Application (2025-2030) & (K Pcs)
Table 83. Global Multiple Sclerosis (MS) Drugs Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 84. Bayer AG Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 86. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 87. Bayer AG Main Business
Table 88. Bayer AG Latest Developments
Table 89. Bayhill Therapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 90. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 91. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 92. Bayhill Therapeutics Main Business
Table 93. Bayhill Therapeutics Latest Developments
Table 94. Biogen Idec Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 96. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 97. Biogen Idec Main Business
Table 98. Biogen Idec Latest Developments
Table 99. Cinnagen Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 101. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 102. Cinnagen Main Business
Table 103. Cinnagen Latest Developments
Table 104. Daiichi Sankyo Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 106. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 107. Daiichi Sankyo Main Business
Table 108. Daiichi Sankyo Latest Developments
Table 109. Eli Lilly Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 111. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 112. Eli Lilly Main Business
Table 113. Eli Lilly Latest Developments
Table 114. Fast Forward Llc Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 116. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 117. Fast Forward Llc Main Business
Table 118. Fast Forward Llc Latest Developments
Table 119. Antisense Therapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 121. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 122. Antisense Therapeutics Main Business
Table 123. Antisense Therapeutics Latest Developments
Table 124. Apitope Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. Apitope Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 126. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 127. Apitope Main Business
Table 128. Apitope Latest Developments
Table 129. Five Prime Therapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 130. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 131. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 132. Five Prime Therapeutics Main Business
Table 133. Five Prime Therapeutics Latest Developments
Table 134. Genmab Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 135. Genmab Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 136. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 137. Genmab Main Business
Table 138. Genmab Latest Developments
Table 139. Artielle Immunotherapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 140. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 141. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 142. Artielle Immunotherapeutics Main Business
Table 143. Artielle Immunotherapeutics Latest Developments
Table 144. Genzyme Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 145. Genzyme Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 146. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 147. Genzyme Main Business
Table 148. Genzyme Latest Developments
Table 149. Glaxosmithkline Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 150. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 151. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 152. Glaxosmithkline Main Business
Table 153. Glaxosmithkline Latest Developments
Table 154. Gw Pharmaceuticals Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 155. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 156. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 157. Gw Pharmaceuticals Main Business
Table 158. Gw Pharmaceuticals Latest Developments
Table 159. Innate Immunotherapeutics Basic Information, Multiple Sclerosis (MS) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 160. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolios and Specifications
Table 161. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 162. Innate Immunotherapeutics Main Business
Table 163. Innate Immunotherapeutics Latest Developments
LIST OF FIGURES
Figure 1. Picture of Multiple Sclerosis (MS) Drugs
Figure 2. Multiple Sclerosis (MS) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Multiple Sclerosis (MS) Drugs Sales Growth Rate 2019-2030 (K Pcs)
Figure 7. Global Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Multiple Sclerosis (MS) Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Copaxone (Glatiramer Acetate, Copolymer 1)
Figure 10. Product Picture of Novantrone (Mitoxantrone)
Figure 11. Product Picture of Gilenya (Fingolimod, Fty720)
Figure 12. Product Picture of Aubagio (Teriflunomide)
Figure 13. Product Picture of Tecfidera (Dimethyl Fumarate)
Figure 14. Product Picture of Firategrast (Sb683699, T-0047)
Figure 15. Product Picture of Siponimod (Baf312)
Figure 16. Product Picture of Others
Figure 17. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2023
Figure 18. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2019-2024)
Figure 19. Multiple Sclerosis (MS) Drugs Consumed in RRMS
Figure 20. Global Multiple Sclerosis (MS) Drugs Market: RRMS (2019-2024) & (K Pcs)
Figure 21. Multiple Sclerosis (MS) Drugs Consumed in SPMS
Figure 22. Global Multiple Sclerosis (MS) Drugs Market: SPMS (2019-2024) & (K Pcs)
Figure 23. Multiple Sclerosis (MS) Drugs Consumed in PPMS
Figure 24. Global Multiple Sclerosis (MS) Drugs Market: PPMS (2019-2024) & (K Pcs)
Figure 25. Multiple Sclerosis (MS) Drugs Consumed in PRMS
Figure 26. Global Multiple Sclerosis (MS) Drugs Market: PRMS (2019-2024) & (K Pcs)
Figure 27. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2023)
Figure 28. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application in 2023
Figure 29. Multiple Sclerosis (MS) Drugs Sales Market by Company in 2023 (K Pcs)
Figure 30. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Company in 2023
Figure 31. Multiple Sclerosis (MS) Drugs Revenue Market by Company in 2023 ($ Million)
Figure 32. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company in 2023
Figure 33. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 34. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Geographic Region in 2023
Figure 35. Americas Multiple Sclerosis (MS) Drugs Sales 2019-2024 (K Pcs)
Figure 36. Americas Multiple Sclerosis (MS) Drugs Revenue 2019-2024 ($ Millions)
Figure 37. APAC Multiple Sclerosis (MS) Drugs Sales 2019-2024 (K Pcs)
Figure 38. APAC Multiple Sclerosis (MS) Drugs Revenue 2019-2024 ($ Millions)
Figure 39. Europe Multiple Sclerosis (MS) Drugs Sales 2019-2024 (K Pcs)
Figure 40. Europe Multiple Sclerosis (MS) Drugs Revenue 2019-2024 ($ Millions)
Figure 41. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales 2019-2024 (K Pcs)
Figure 42. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue 2019-2024 ($ Millions)
Figure 43. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2023
Figure 44. Americas Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2023
Figure 45. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Figure 46. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Figure 47. United States Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 48. Canada Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 49. Mexico Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 50. Brazil Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 51. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Region in 2023
Figure 52. APAC Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions in 2023
Figure 53. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Figure 54. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Figure 55. China Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 56. Japan Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 57. South Korea Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 58. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 59. India Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 60. Australia Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 61. China Taiwan Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 62. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2023
Figure 63. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2023
Figure 64. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Figure 65. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Figure 66. Germany Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 67. France Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 68. UK Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 69. Italy Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 70. Russia Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 71. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2023
Figure 72. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2023
Figure 73. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Figure 74. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Figure 75. Egypt Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 76. South Africa Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 77. Israel Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 78. Turkey Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 79. GCC Country Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs in 2023
Figure 81. Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
Figure 82. Industry Chain Structure of Multiple Sclerosis (MS) Drugs
Figure 83. Channels of Distribution
Figure 84. Global Multiple Sclerosis (MS) Drugs Sales Market Forecast by Region (2025-2030)
Figure 85. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 86. Global Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 87. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 88. Global Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 89. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Multiple Sclerosis (MS) Drugs
Figure 2. Multiple Sclerosis (MS) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Multiple Sclerosis (MS) Drugs Sales Growth Rate 2019-2030 (K Pcs)
Figure 7. Global Multiple Sclerosis (MS) Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Multiple Sclerosis (MS) Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Copaxone (Glatiramer Acetate, Copolymer 1)
Figure 10. Product Picture of Novantrone (Mitoxantrone)
Figure 11. Product Picture of Gilenya (Fingolimod, Fty720)
Figure 12. Product Picture of Aubagio (Teriflunomide)
Figure 13. Product Picture of Tecfidera (Dimethyl Fumarate)
Figure 14. Product Picture of Firategrast (Sb683699, T-0047)
Figure 15. Product Picture of Siponimod (Baf312)
Figure 16. Product Picture of Others
Figure 17. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type in 2023
Figure 18. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2019-2024)
Figure 19. Multiple Sclerosis (MS) Drugs Consumed in RRMS
Figure 20. Global Multiple Sclerosis (MS) Drugs Market: RRMS (2019-2024) & (K Pcs)
Figure 21. Multiple Sclerosis (MS) Drugs Consumed in SPMS
Figure 22. Global Multiple Sclerosis (MS) Drugs Market: SPMS (2019-2024) & (K Pcs)
Figure 23. Multiple Sclerosis (MS) Drugs Consumed in PPMS
Figure 24. Global Multiple Sclerosis (MS) Drugs Market: PPMS (2019-2024) & (K Pcs)
Figure 25. Multiple Sclerosis (MS) Drugs Consumed in PRMS
Figure 26. Global Multiple Sclerosis (MS) Drugs Market: PRMS (2019-2024) & (K Pcs)
Figure 27. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2023)
Figure 28. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application in 2023
Figure 29. Multiple Sclerosis (MS) Drugs Sales Market by Company in 2023 (K Pcs)
Figure 30. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Company in 2023
Figure 31. Multiple Sclerosis (MS) Drugs Revenue Market by Company in 2023 ($ Million)
Figure 32. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company in 2023
Figure 33. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 34. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Geographic Region in 2023
Figure 35. Americas Multiple Sclerosis (MS) Drugs Sales 2019-2024 (K Pcs)
Figure 36. Americas Multiple Sclerosis (MS) Drugs Revenue 2019-2024 ($ Millions)
Figure 37. APAC Multiple Sclerosis (MS) Drugs Sales 2019-2024 (K Pcs)
Figure 38. APAC Multiple Sclerosis (MS) Drugs Revenue 2019-2024 ($ Millions)
Figure 39. Europe Multiple Sclerosis (MS) Drugs Sales 2019-2024 (K Pcs)
Figure 40. Europe Multiple Sclerosis (MS) Drugs Revenue 2019-2024 ($ Millions)
Figure 41. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales 2019-2024 (K Pcs)
Figure 42. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue 2019-2024 ($ Millions)
Figure 43. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2023
Figure 44. Americas Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2023
Figure 45. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Figure 46. Americas Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Figure 47. United States Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 48. Canada Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 49. Mexico Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 50. Brazil Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 51. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Region in 2023
Figure 52. APAC Multiple Sclerosis (MS) Drugs Revenue Market Share by Regions in 2023
Figure 53. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Figure 54. APAC Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Figure 55. China Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 56. Japan Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 57. South Korea Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 58. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 59. India Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 60. Australia Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 61. China Taiwan Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 62. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2023
Figure 63. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2023
Figure 64. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Figure 65. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Figure 66. Germany Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 67. France Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 68. UK Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 69. Italy Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 70. Russia Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 71. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country in 2023
Figure 72. Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Country in 2023
Figure 73. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2019-2024)
Figure 74. Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2019-2024)
Figure 75. Egypt Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 76. South Africa Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 77. Israel Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 78. Turkey Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 79. GCC Country Multiple Sclerosis (MS) Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs in 2023
Figure 81. Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
Figure 82. Industry Chain Structure of Multiple Sclerosis (MS) Drugs
Figure 83. Channels of Distribution
Figure 84. Global Multiple Sclerosis (MS) Drugs Sales Market Forecast by Region (2025-2030)
Figure 85. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 86. Global Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 87. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 88. Global Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 89. Global Multiple Sclerosis (MS) Drugs Revenue Market Share Forecast by Application (2025-2030)
